Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03909334 · ClinicalTrials.gov registry record · Phase 2
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer, sponsored by Xiuning Le.
- Active
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 12
- Study locations
NCT03909334: Active Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer, sponsored by Xiuning Le.
NCT03909334 is a Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer that is active but no longer recruiting, run by Xiuning Le. The registered enrollment target is 160 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03909334, a Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer, is active but no longer recruiting, sponsored by Xiuning Le.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
Primary Outcome
Progression free survival (PFS) time will be calculated from the date of randomization to disease progression or death from any cause, whichever occurs the first.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Ramucirumab
Study Locations (12)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- Rush University Medical Center - Chicago
New York
- New York University Cancer Center - New York
- Columbia University Irving Medical Center - New York
District of Columbia
- Georgetown University - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Indiana
- Indiana Univesity Melvin and Bren Simon Cancer Center - Indianapolis
New Jersey
- Summit Medical Group, PA - Berkeley Heights
Oregon
- Providence Portland Medical Center - Portland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
What the registry record for NCT03909334 still lists
NCT03909334 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT03909334 lists 12 locations in 10 states (Illinois, New York, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT03909334 about?
NCT03909334 is a clinical study titled "Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled a...
What is the current status of trial NCT03909334?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2019-07-25. Estimated completion is 2026-01.
What conditions does trial NCT03909334 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer, EGFR Gene Mutation.
What interventions are being tested in trial NCT03909334?
The interventions under investigation include: Osimertinib (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT03909334?
This trial is sponsored by Xiuning Le, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03909334 being conducted?
This trial has 12 study locations across District of Columbia, Florida, Illinois, Indiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03909334's enrollment target sits among peer trials
160 192nd of 454 higher than 262 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI